Zurcher Kantonalbank Zurich Cantonalbank Purchases 161,816 Shares of Johnson & Johnson $JNJ

Key Points

• Zurcher Kantonalbank increased its stake in Johnson & Johnson by 11.7% in Q4, buying 161,816 shares to hold 1,545,618 shares worth roughly $319.9 million, representing about 0.06% of JNJ and the bank's 18th largest position.
• Johnson & Johnson slightly beat Q1 estimates with EPS $2.70 vs. $2.68 and revenue $24.06 billion vs. $23.60 billion, and set FY2026 EPS guidance of 11.45–11.65.
• J&J raised its quarterly dividend to $1.34 ($5.36 annual, ~2.3% yield), while analysts maintain a "Moderate Buy" consensus with an average target around $252.48 and several firms lifting targets (Goldman Sachs to $275).

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,545,618 shares of the company's stock after buying an additional 161,816 shares during the period. Johnson & Johnson comprises approximately 0.7% of Zurcher Kantonalbank Zurich Cantonalbank's holdings, making the stock its 18th largest position. Zurcher Kantonalbank Zurich Cantonalbank owned 0.06% of Johnson & Johnson worth $319,866,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after purchasing an additional 956,239 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after buying an additional 835,146 shares in the last quarter. Legal & General Group Plc raised its position in shares of Johnson & Johnson by 2.8% during the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after buying an additional 532,790 shares during the last quarter. Amundi boosted its position in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock worth $2,512,719,000 after acquiring an additional 2,163,838 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its position in shares of Johnson & Johnson by 7.3% during the third quarter. Raymond James Financial Inc. now owns 10,137,651 shares of the company's stock worth $1,879,718,000 after acquiring an additional 690,887 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 2.0%

Shares of NYSE JNJ opened at $230.67 on Friday. The stock has a market capitalization of $555.60 billion, a P/E ratio of 26.67, a PEG ratio of 2.21 and a beta of 0.34. Johnson & Johnson has a 1-year low of $146.12 and a 1-year high of $251.71. The business's 50 day moving average is $240.50 and its two-hundred day moving average is $218.19. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.75% and a net margin of 21.83%.The company's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is presently 60.12%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on JNJ shares. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Weiss Ratings restated a "buy (b)" rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Stifel Nicolaus increased their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research report on Wednesday, April 15th. Finally, Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a "market perform" rating in a report on Wednesday, April 15th. Eighteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $252.48.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Long‑term Phase 3/extension data for IMAAVY (nipocalimab) show sustained clinical benefit and safety through ~2 years in generalized myasthenia gravis, boosting revenue visibility for J&J’s autoimmune franchise and supporting durable upside for the Innovative Medicine segment. IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
• Positive Sentiment: The stock snapped a six‑session losing streak as momentum returned; traders appear to be buying the rebound on the above clinical and corporate catalysts rather than fresh negative fundamentals. JNJ snaps six straight sessions of losses
• Positive Sentiment: Johnson & Johnson entered a commercialization collaboration with Viz.ai to integrate AI‑powered subdural hemorrhage detection into its neurovascular offerings, a strategic move that could improve hospital workflows and expand device/software revenue streams. Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care
• Positive Sentiment: Ethicon secured CE mark for its new Ethicon 4000 surgical stapler, a regulatory win that supports J&J’s MedTech growth and potential incremental sales in international markets. Johnson & Johnson wins CE mark for new Ethicon 4000 surgical stapler
• Positive Sentiment: High‑profile media/TV endorsements (Jim Cramer bought JNJ on Mad Money) and inclusion in “best counter‑cyclical” lists are providing positive sentiment momentum among retail and dividend investors. Jim Cramer Called Johnson & Johnson “The Best Drug Stock, or at Least the Second-Best”
• Neutral Sentiment: Analyst and media coverage is framing J&J as a counter‑cyclical/dividend holding that can steady portfolios; such positioning attracts yield seekers but may limit short‑term upside to valuation and growth execution. Is Johnson & Johnson (JNJ) the Best Counter Cyclical Stock to Buy Right Now?
• Neutral Sentiment: Investors should still watch product‑level pressures (e.g., prior references to Stelara dynamics) and execution risks; J&J’s recent Q1 beat and FY‑2026 EPS guide mitigate but do not eliminate these uncertainties. Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.